US6403599B1
(en)
|
1995-11-08 |
2002-06-11 |
Pfizer Inc |
Corticotropin releasing factor antagonists
|
TW544448B
(en)
|
1997-07-11 |
2003-08-01 |
Novartis Ag |
Pyridine derivatives
|
DE19735879A1
(de)
|
1997-08-19 |
1999-02-25 |
Hoechst Schering Agrevo Gmbh |
Verfahren zur Herstellung von 2-Carboxy-5-nitro-benzolsulfonsäure und deren Salzen durch Oxidation
|
GB9802251D0
(en)
|
1998-02-03 |
1998-04-01 |
Ciba Geigy Ag |
Organic compounds
|
PT1117403E
(pt)
|
1998-10-02 |
2004-04-30 |
Sibia Neurosciences Inc |
Antagonistas de mglurs para o tratamento da dor e ansiedade
|
US6525203B1
(en)
|
1999-03-12 |
2003-02-25 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
GB0028702D0
(en)
|
2000-11-24 |
2001-01-10 |
Novartis Ag |
Organic compounds
|
SK11952003A3
(sk)
|
2001-03-26 |
2004-03-02 |
Novartis Ag |
Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
|
JP3894035B2
(ja)
|
2001-07-04 |
2007-03-14 |
東レ株式会社 |
炭素繊維強化基材、それからなるプリフォームおよび複合材料
|
TW200306839A
(en)
|
2002-02-06 |
2003-12-01 |
Novartis Ag |
Quinazolinone derivatives and their use as CB agonists
|
US6696468B2
(en)
|
2002-05-16 |
2004-02-24 |
Dainippon Pharmaceutical Co., Ltd. |
(s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
|
SE0201940D0
(sv)
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
New combination II
|
DOP2003000703A
(es)
|
2002-09-20 |
2004-03-31 |
Pfizer |
Compuestos de imidazopiradina como agonistas del receptor 5-ht4
|
GB0223730D0
(en)
|
2002-10-11 |
2002-11-20 |
Novartis Ag |
Organic compounds
|
PE20040844A1
(es)
|
2002-11-26 |
2004-12-30 |
Novartis Ag |
Acidos fenilaceticos y derivados como inhibidores de la cox-2
|
GB0302876D0
(en)
|
2003-02-07 |
2003-03-12 |
Novartis Ag |
Organic compounds
|
JP2004277318A
(ja)
|
2003-03-14 |
2004-10-07 |
Dainippon Pharmaceut Co Ltd |
1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物
|
JP2004277319A
(ja)
|
2003-03-14 |
2004-10-07 |
Dainippon Pharmaceut Co Ltd |
1−(4−ピペリジニルメチル)ピペリジニルアミド誘導体およびそれを含有する医薬組成物
|
US7491695B2
(en)
|
2003-06-18 |
2009-02-17 |
Tranzyme Pharma Inc. |
Methods of using macrocyclic modulators of the ghrelin receptor
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
EP1505064A1
(en)
|
2003-08-05 |
2005-02-09 |
Bayer HealthCare AG |
2-Aminopyrimidine derivatives
|
WO2005013997A1
(en)
|
2003-08-12 |
2005-02-17 |
F. Hoffmann-La Roche Ag |
Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
|
JP2007501821A
(ja)
|
2003-08-12 |
2007-02-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
Cfrアンタゴニストとしてのテトラヒドロキナゾリン誘導体
|
EP1664010A1
(en)
|
2003-08-29 |
2006-06-07 |
Vernalis (R&D) Limited |
Sulfonamides antagonising n-type calcium channels
|
EP1675858A2
(en)
|
2003-09-03 |
2006-07-05 |
Neurogen Corporation |
5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
|
OA13248A
(en)
|
2003-09-03 |
2007-01-31 |
Pfizer |
Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
|
JP2005082508A
(ja)
|
2003-09-05 |
2005-03-31 |
Dainippon Pharmaceut Co Ltd |
2−アルコキシ−6−アミノ−5−ハロゲノ−n−(1−置換−4−ピペリジニル)ピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物
|
CN1878773A
(zh)
|
2003-09-05 |
2006-12-13 |
神经能质公司 |
作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
|
AU2004272437A1
(en)
|
2003-09-09 |
2005-03-24 |
Ono Pharmaceutical Co., Ltd. |
CRF antagonists and heterobicyclic compounds
|
GB0322612D0
(en)
|
2003-09-26 |
2003-10-29 |
Novartis Ag |
Organic compounds
|
CN1886380B
(zh)
|
2003-09-30 |
2010-12-22 |
詹森药业有限公司 |
苯并咪唑化合物
|
MXPA06003578A
(es)
|
2003-09-30 |
2006-08-31 |
Johnson & Johnson |
Compuestos de quinoxalina.
|
JP2005104896A
(ja)
|
2003-09-30 |
2005-04-21 |
Dainippon Pharmaceut Co Ltd |
2−アルコキシ−6−アミノ−5−ハロゲノピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物
|
JP4842829B2
(ja)
|
2003-10-31 |
2011-12-21 |
武田薬品工業株式会社 |
含窒素縮合複素環化合物
|
CN1870999A
(zh)
|
2003-10-31 |
2006-11-29 |
阿斯利康(瑞典)有限公司 |
炔烃ⅰ
|
EP1694654B1
(en)
|
2003-11-10 |
2011-03-02 |
Merck Sharp & Dohme Corp. |
Substituted triazoles as sodium channel blockers
|
US7208596B2
(en)
|
2003-11-25 |
2007-04-24 |
Bristol-Myers Squibb Pharma Company |
Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
|
WO2005054239A1
(en)
|
2003-12-05 |
2005-06-16 |
Bayer Healthcare Ag |
2-aminopyrimidine derivatives
|
US7211568B2
(en)
|
2003-12-18 |
2007-05-01 |
Kosan Biosciences Incorporated |
9-Desoxoerythromycin compounds as prokinetic agents
|
US20070255061A1
(en)
|
2003-12-19 |
2007-11-01 |
Astrazeneca Ab |
5-Fluoro-, Chloro-and Cyano-Pyridin-2-Yl-Tetrazoles as Ligands of the Metabotropic Glutamate Receptor-5
|
JP2005206590A
(ja)
|
2003-12-25 |
2005-08-04 |
Mitsubishi Pharma Corp |
ナトリウムチャネルサイト2選択的阻害剤
|
AU2005205531B2
(en)
|
2004-01-07 |
2011-03-17 |
Renexxion, Llc |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
TW200530181A
(en)
|
2004-01-13 |
2005-09-16 |
Bristol Myers Squibb Co |
Heterocyclic compounds useful as growth hormone secretagogues
|
US7691881B2
(en)
|
2004-01-29 |
2010-04-06 |
Pfizer Inc |
1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
JP2007523178A
(ja)
|
2004-02-18 |
2007-08-16 |
アストラゼネカ アクチボラグ |
代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用
|
CA2556320A1
(en)
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists for the treatment of gastrointestinal disorders
|
EP1716130A1
(en)
|
2004-02-18 |
2006-11-02 |
AstraZeneca AB |
Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
TW200533348A
(en)
|
2004-02-18 |
2005-10-16 |
Theravance Inc |
Indazole-carboxamide compounds as 5-ht4 receptor agonists
|
SG150539A1
(en)
|
2004-02-18 |
2009-03-30 |
Astrazeneca Ab |
Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
|
RU2381226C2
(ru)
|
2004-02-18 |
2010-02-10 |
Астразенека Аб |
Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
|
TW200538108A
(en)
|
2004-02-19 |
2005-12-01 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
TW200538180A
(en)
|
2004-02-20 |
2005-12-01 |
Astrazeneca Ab |
New compounds
|
WO2005092882A1
(en)
|
2004-03-01 |
2005-10-06 |
Pfizer Japan, Inc. |
4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
|
JP5162236B2
(ja)
|
2004-03-25 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
イミダゾール化合物
|
US20080280873A1
(en)
|
2004-03-29 |
2008-11-13 |
Jun Liang |
Biaryl Substituted Pyrazinones as Sodium Channel Blockers
|
WO2005097788A2
(en)
|
2004-04-02 |
2005-10-20 |
Elixir Pharmaceuticals, Inc. |
Sulfonamides and uses thereof
|
TWI351282B
(en)
|
2004-04-07 |
2011-11-01 |
Theravance Inc |
Quinolinone-carboxamide compounds as 5-ht4 recepto
|
US20080015196A1
(en)
|
2004-04-16 |
2008-01-17 |
Neurogen Corporation |
Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
|
GB0412769D0
(en)
|
2004-06-08 |
2004-07-07 |
Novartis Ag |
Organic compounds
|
GB0412768D0
(en)
|
2004-06-08 |
2004-07-07 |
Novartis Ag |
Organic compounds
|
PE20060526A1
(es)
|
2004-06-15 |
2006-07-13 |
Schering Corp |
Compuestos triciclicos como antagonistas de mglur1
|
GEP20094638B
(en)
|
2004-06-15 |
2009-03-10 |
Pfizer |
Benzimidazolone carboxylic acid derivatives
|
SE0401653D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
US20060035939A1
(en)
|
2004-07-14 |
2006-02-16 |
Japan Tobacco Inc. |
3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
|
BRPI0513286A
(pt)
|
2004-07-15 |
2008-05-06 |
Japan Tobacco Inc |
compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
|
ES2333889T3
(es)
|
2004-07-19 |
2010-03-02 |
Institut De Recherche Pour Le Developpement (Ird) |
Composiciones farmaceuticas para el tratamiento de la leishmaniasis.
|
CA2575359A1
(en)
|
2004-07-28 |
2006-02-02 |
Glaxo Group Limited |
Piperazine derivatives useful for the treatment of gastrointestinal disorders
|
ITMI20041566A1
(it)
|
2004-07-30 |
2004-10-30 |
Indena Spa |
"trpv1 agonisti, formulazioni che li contengono e loro usi"
|
WO2006016218A1
(en)
|
2004-08-03 |
2006-02-16 |
Pfizer Japan Inc. |
Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
|
WO2006023757A2
(en)
|
2004-08-19 |
2006-03-02 |
University Of Virginia Patent Foundation |
Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
|
AU2005284904A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
GB0420424D0
(en)
|
2004-09-14 |
2004-10-20 |
Ionix Pharmaceuticals Ltd |
Therapeutic compounds
|
SE0402284D0
(sv)
|
2004-09-21 |
2004-09-21 |
Astrazeneca Ab |
New heterocyclic amides
|
US20080261970A1
(en)
|
2004-09-27 |
2008-10-23 |
Elixir Pharmaceuticals, Inc. |
Sufonamides and Uses Thereof
|
WO2006038594A1
(ja)
|
2004-10-04 |
2006-04-13 |
Ono Pharmaceutical Co., Ltd. |
N型カルシウムチャネル阻害薬
|
JP5635727B2
(ja)
|
2004-10-07 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法
|
US20080070946A1
(en)
|
2004-10-08 |
2008-03-20 |
Astrazeneca Ab |
Hydroxymethylbenzothiazoles Amides
|
US8143425B2
(en)
|
2004-10-12 |
2012-03-27 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
CA2583392A1
(en)
|
2004-10-15 |
2006-04-27 |
Amgen Inc. |
Imidazole derivatives as vanilloid receptor ligands
|
GB0519957D0
(en)
|
2005-09-30 |
2005-11-09 |
Sb Pharmco Inc |
Chemical compound
|
JP2008517060A
(ja)
|
2004-10-19 |
2008-05-22 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
Crf受容体アンタゴニストおよびその製法
|
WO2006047492A2
(en)
|
2004-10-22 |
2006-05-04 |
Amgen Inc. |
Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
|
EP1809620B1
(en)
|
2004-11-04 |
2010-12-29 |
Addex Pharma SA |
Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
|
DE602005014566D1
(de)
|
2004-11-05 |
2009-07-02 |
Theravance Inc |
Chinolinon-carboxamid-verbindungen
|
DE602005016446D1
(de)
|
2004-11-05 |
2009-10-15 |
Theravance Inc |
5-HT4-Rezeptoragonistenverbindungen
|
EP1812113A1
(en)
|
2004-11-11 |
2007-08-01 |
Argenta Discovery Limited |
Pyrimidine compounds as histamine modulators
|
US20060111416A1
(en)
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
US7812019B2
(en)
|
2004-11-24 |
2010-10-12 |
Abbott Laboratories |
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
|
WO2006058338A2
(en)
|
2004-11-29 |
2006-06-01 |
Janssen Pharmaceutica N.V. |
4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
|
US7875627B2
(en)
|
2004-12-07 |
2011-01-25 |
Abbott Laboratories |
Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
|
US20060128710A1
(en)
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
US7615570B2
(en)
|
2004-12-13 |
2009-11-10 |
Abbott Laboratories |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
SE0403118D0
(sv)
|
2004-12-21 |
2004-12-21 |
Astrazeneca Ab |
New compounds 2
|
SE0403117D0
(sv)
|
2004-12-21 |
2004-12-21 |
Astrazeneca Ab |
New compounds 1
|
CA2588037A1
(en)
|
2004-12-22 |
2006-06-29 |
Theravance, Inc. |
Indazole-carboxamide compounds
|
SE0403171D0
(sv)
|
2004-12-23 |
2004-12-23 |
Astrazeneca Ab |
New compounds
|
CA2593439C
(en)
|
2005-01-14 |
2014-02-25 |
F. Hoffmann-La Roche Ag |
Thiazole-4-carboxamide derivatives as mglur5 antagonists
|
US20080085901A1
(en)
|
2005-01-14 |
2008-04-10 |
Neurogen Corporation |
Heteroaryl Substituted Quinolin-4-Ylamine Analogues
|
US7429608B2
(en)
|
2005-01-20 |
2008-09-30 |
Amgen Inc. |
Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
|
WO2006089311A1
(en)
|
2005-02-15 |
2006-08-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
JP2008530225A
(ja)
|
2005-02-17 |
2008-08-07 |
セラヴァンス, インコーポレーテッド |
インダゾール−カルボキサミド化合物の結晶型
|
GB0503646D0
(en)
|
2005-02-22 |
2005-03-30 |
Novartis Ag |
Organic compounds
|
ES2346147T3
(es)
|
2005-03-03 |
2010-10-11 |
Janssen Pharmaceutica Nv |
Derivados de oxa-diaza-espiro-(5.5)-undecanona sustituidos y su uso como antagonistas de las neuroquininas.
|
EP1858865B1
(en)
|
2005-03-10 |
2009-09-16 |
Pfizer Inc. |
Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
|
US20060211710A1
(en)
|
2005-03-17 |
2006-09-21 |
Pfizer Inc |
Substituted aryl 1,4-pyrazine derivatives
|
CA2602583A1
(en)
|
2005-03-24 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Biaryl derived amide modulators of vanilloid vr1 receptor
|
GB0506147D0
(en)
|
2005-03-24 |
2005-05-04 |
Merck Sharp & Dohme |
Therapeutic agents
|
US20060293309A1
(en)
|
2005-03-28 |
2006-12-28 |
Dynogen Pharmaceuticals, Inc. |
Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
|
TWI377206B
(en)
|
2005-04-06 |
2012-11-21 |
Theravance Inc |
Crystalline form of a quinolinone-carboxamide compound
|
EP1877400A1
(en)
|
2005-04-15 |
2008-01-16 |
Amgen, Inc |
Vanilloid receptor ligands and their use in treatments
|
GB0508314D0
(en)
|
2005-04-25 |
2005-06-01 |
Novartis Ag |
Organic compounds
|
GB0508318D0
(en)
|
2005-04-25 |
2005-06-01 |
Novartis Ag |
Organic compounds
|
WO2006116563A1
(en)
|
2005-04-25 |
2006-11-02 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
GB0508319D0
(en)
|
2005-04-25 |
2005-06-01 |
Novartis Ag |
Organic compounds
|
CN101248052A
(zh)
|
2005-05-11 |
2008-08-20 |
艾博特公司 |
香草素受体亚型1(vr1)拮抗剂及其用途
|
EP1881988A1
(en)
|
2005-05-11 |
2008-01-30 |
MERCK SHARP & DOHME LTD. |
2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
|
GB0509573D0
(en)
|
2005-05-11 |
2005-06-15 |
Merck Sharp & Dohme |
Therapeutic compounds
|
US20060281718A1
(en)
|
2005-05-12 |
2006-12-14 |
Bannon Anthony W |
Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent
|
DE102005038947A1
(de)
|
2005-05-18 |
2006-11-30 |
Grünenthal GmbH |
Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
|
GB0510140D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B2
|
EA015813B1
(ru)
|
2005-05-18 |
2011-12-30 |
Аддекс Фарма Са |
Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
|
GB0510139D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B1
|
GB0510141D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B3
|
DE102005023588A1
(de)
|
2005-05-18 |
2006-11-23 |
Grünenthal GmbH |
Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
|
GB0510142D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
DE102005023784A1
(de)
|
2005-05-19 |
2006-11-30 |
Grünenthal GmbH |
Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
|
DE102005044813A1
(de)
|
2005-05-19 |
2007-10-04 |
Grünenthal GmbH |
Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
|
DE102005044814A1
(de)
|
2005-05-19 |
2006-11-23 |
Grünenthal GmbH |
Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
|
DE102005024012A1
(de)
|
2005-05-20 |
2006-11-23 |
Grünenthal GmbH |
Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
|
US7582611B2
(en)
|
2005-05-24 |
2009-09-01 |
Pfizer Inc. |
Motilide compounds
|
MY147756A
(en)
|
2005-05-25 |
2013-01-15 |
Theravance Inc |
Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
|
JP5086248B2
(ja)
|
2005-06-07 |
2012-11-28 |
セラヴァンス, インコーポレーテッド |
5−ht4受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物
|
EP1893569A4
(en)
|
2005-06-10 |
2009-08-05 |
Elixir Pharmaceuticals Inc |
SULPHONAMIDE COMPOUNDS AND ITS USES
|
CN101203511A
(zh)
|
2005-06-23 |
2008-06-18 |
阿斯利康(瑞典)有限公司 |
作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
|
CN101208327A
(zh)
|
2005-06-23 |
2008-06-25 |
阿斯利康(瑞典)有限公司 |
作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
|
CA2612893A1
(en)
|
2005-07-05 |
2007-01-11 |
Aryx Therapeutics, Inc. |
Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
WO2007004041A2
(en)
|
2005-07-05 |
2007-01-11 |
Orchid Research Laboratories Limited |
New compounds and their pharmaceutical use
|
JP2009501199A
(ja)
|
2005-07-12 |
2009-01-15 |
グラクソ グループ リミテッド |
Gpr38アゴニストとしてのピペラジンヘテロアリール誘導体
|
US7906532B2
(en)
|
2005-07-22 |
2011-03-15 |
Pfizer Inc. |
Indazole derivatives
|
CA2616396C
(en)
|
2005-07-22 |
2013-07-23 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Growth hormone secretagogues
|
EP1757290A1
(en)
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
|
WO2007023242A1
(en)
|
2005-08-24 |
2007-03-01 |
Merz Pharma Gmbh & Co. Kgaa |
Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
|
EP1943247A1
(en)
|
2005-08-25 |
2008-07-16 |
Merz Pharma GmbH & Co.KGaA |
Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
|
JP2009507855A
(ja)
|
2005-09-08 |
2009-02-26 |
スミスクライン・ビーチャム・コーポレイション |
非環式1,4−ジアミンおよびその使用
|
BRPI0615880A2
(pt)
|
2005-09-13 |
2011-05-31 |
Palau Pharma Sa |
compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
|
AR057828A1
(es)
|
2005-09-29 |
2007-12-19 |
Astrazeneca Ab |
Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
|
AR056087A1
(es)
|
2005-09-29 |
2007-09-19 |
Astrazeneca Ab |
Derivados de azetidina como antagonistas de receptores de neuroquina nk
|
AR058807A1
(es)
|
2005-09-29 |
2008-02-27 |
Astrazeneca Ab |
5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
|
HUP0500921A2
(en)
|
2005-10-05 |
2007-07-30 |
Richter Gedeon Nyrt |
Tetrazole derivatives, process for their preparation and their use
|
HUP0500920A2
(en)
|
2005-10-05 |
2007-07-30 |
Richter Gedeon Nyrt |
Oxadiazole derivatives, process for their preparation and their use
|
CA2624307C
(en)
|
2005-10-07 |
2014-04-29 |
Glenmark Pharmaceuticals S.A. |
Substituted benzofused derivatives and their use as vanilloid receptor ligands
|
EP2388258A1
(de)
|
2005-10-19 |
2011-11-23 |
Grünenthal GmbH |
Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
|
US20070088073A1
(en)
|
2005-10-19 |
2007-04-19 |
Allergan, Inc. |
Method for treating pain
|
US7902251B2
(en)
|
2005-10-19 |
2011-03-08 |
Allergan, Inc. |
Method for treating pain
|
EP1957464A1
(en)
|
2005-10-28 |
2008-08-20 |
Abbott Laboratories |
INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR
|
US20070105920A1
(en)
|
2005-11-08 |
2007-05-10 |
Akzo Nobel N.V. |
2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
|
GB0525068D0
(en)
|
2005-12-08 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
WO2007090853A1
(en)
|
2006-02-10 |
2007-08-16 |
Cellzome (Uk) Ltd. |
Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders
|
WO2007090854A1
(en)
|
2006-02-10 |
2007-08-16 |
Cellzome (Uk) Ltd. |
Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
|
EP1829879A1
(en)
|
2006-02-10 |
2007-09-05 |
Cellzome (UK) Ltd. |
Amino pyrimidine compounds for the treatment of inflammatory disorders
|
PT2007752E
(pt)
|
2006-03-31 |
2010-10-18 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4
|
JP2009532367A
(ja)
|
2006-03-31 |
2009-09-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリジン
|
JP2009531385A
(ja)
|
2006-03-31 |
2009-09-03 |
グラクソ グループ リミテッド |
成長ホルモン分泌促進物質(ghs)受容体アゴニストとしてのピペラジン誘導体
|
EP2010172B1
(en)
|
2006-04-07 |
2012-08-29 |
Janssen Pharmaceutica N.V. |
Indoles and benzoimidazoles as modulators of the histamine h4 receptor
|
JP2010523466A
(ja)
|
2006-04-13 |
2010-07-15 |
グラクソ グループ リミテッド |
成長ホルモン分泌促進因子受容体アゴニストとしてのアリールおよびヘテロアリールスルホンアミド類
|